Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Immunotherapy has revolutionised medical oncology due to durable responses and favourable clinical trial outcomes seen in some patient populations treated with immune checkpoint inhibitors.1 As a consequence, various immune checkpoint inhibitors have been approved by regulatory bodies and have quickly been adpoted as the standard treatment option in several cancer types, such as melanoma, lung cancer and renal cell cancer.2–8 Efficacy has been shown not only in metastatic stages including patients in highly advanced treatment phases but also in patients with lung cancer and melanoma treated in the adjuvant setting.